ClinicalTrials.gg
CompletedNCT02093351Updated Oct 2, 2019Results posted

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

A Phase 1 interventional study of Olaparib and Tamoxifen in Solid Tumours, sponsored by AstraZeneca. Completed at 14 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-10-02.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
79
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice versa; Part B will allow patients (if eligible) continued access to olaparib after the PK phase and will provide additional safety data.

02

Conditions studied

  • Solid Tumours

Browse trials for

Keywords

  • oncology, cancer, tumour, neoplasm, anticancer drug, pharmacokinetics, olaparib, anastrozole, tamoxifen, letrozole,
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 79 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written prior to any study specific procedures
  2. Male or female aged ≥18 years
  3. Histological or cytological confirmation of any malignant solid tumour in an advanced or setting who meet one of the criteria below:

    • Patients should be resistant or to standard treatment if such treatment exists OR
    • Patients for which no suitable effective standard therapy exists OR
    • Patients with advanced breast cancer for whom anastrozole, letrozole or tamoxifen are indicated may also enter the study ( breast cancer patients will be eligible for any of the cohorts; however, premenopausal breast cancer patients will be eligible for the tamoxifen cohort only).
  4. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • (Hb) ≥10.0 g/dL with no blood transfusions in the past 28 days
    • (ANC) ≥1.5 x 109/L
    • count ≥100 x 109/L
    • Total ≤1.5 x institutional (ULN) (except in the case of Gilbert's disease)
    • (AST)/alanine aminotransferase (ALT) ≤2.5 x institutional ULN unless liver metastases are present, in which case they must be ≤5x ULN
    • Serum creatinine ≤1.5 x institutional ULN
  5. (ECOG) performance status 0, 1 or 2
  6. Patients must have a ≥16 weeks
  7. Evidence of non-childbearing status for women of , or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of Part A.

    Postmenopausal is defined as:

    • Age ≥ 60 years
    • Age \<60 years and amenorrheic for 1 year or more in the absence of chemotherapy and/or hormonal treatment
    • Luteinising hormone (LH), follicle stimulating hormone (FSH) and plasma oestradiol levels in the postmenopausal range for women under 60 years
    • Radiation-induced oophorectomy with last menses >1 year ago
    • Or surgical sterilisation (bilateral oophorectomy or hysterectomy)
  8. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment, and scheduled visits and examinations
  9. Patients must be on stable concomitant medication regimen (with the exception of electrolyte supplements), defined as no change in medication or dose within 2 weeks prior to start of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents, and/or staff at the study site)
  2. Previous enrolment in the present study
  3. Exposure to an product (IP) (including PARP inhibitor) within 30 days or 5 half lives (whichever is the longer) prior to enrolment
  4. Prior chemotherapy within 3 weeks of study entry
  5. Prior radiotherapy within 2 weeks of study entry
  6. If prior endocrine treatment is given, adequate is required: at least 2 weeks for anastrozole, at least 4 weeks for letrozole and at least 10 weeks for tamoxifen
  7. Resting with >470 msec detected on 2 or more time points within a 24 hour period, or family history of long QT syndrome. If ECG demonstrates QTc >470 msec, patient will be eligible only if repeat ECG demonstrates QTc \<470 msec.
  8. Patients who are receiving inhibitors or inducers of unless washed out prior to start of study treatment.
  9. Persistent toxicities (Common Toxicity Criteria for Adverse Events [] grade ≥2) caused by previous cancer therapy, excluding alopecia and/or CTCAE grade 2 peripheral neuropathy
  10. Patients with myelodysplastic syndrome/acute myeloid leukaemia
  11. Major surgery within 2 weeks of starting study treatment: patients must have recovered from any effects of any major surgery
  12. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled seizures or active uncontrolled infection.
  13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with absorption of the study medication
  14. Patients who have gastric, gastro-oesophageal, or oesophageal cancer
  15. Pregnant or breastfeeding women
  16. Patients with known active or C, or (HIV).
  17. Patients with a known to olaparib (all cohorts), tamoxifen (Cohort 1) anastrozole (Cohort 2), letrozole (Cohort 3), or any of the of these products.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Cohort 1 - Tamoxifen

    Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.

    Drug: Olaparib · Drug: Tamoxifen · Procedure: Pharmacokinetic sampling

  • Experimental
    Cohort 2 - Anastrozole

    Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.

    Drug: Olaparib · Drug: Anastrozole · Procedure: Pharmacokinetic sampling

  • Experimental
    Cohort 3 - Letrozole

    Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.

    Drug: Olaparib · Drug: Letrozole · Procedure: Pharmacokinetic sampling

Interventions

  • 2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)

  • 60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31

  • 1mg Anastrozole once daily Day 10 - Day 24

  • 2.5mg Letrozole once daily Day 10 - Day 43

  • ProcedurePharmacokinetic sampling

    Blood sampling over 12-24 hour period for pharmacokinetic analysis

06

What researchers measure

Primary outcomes

  1. Effect of Olaparib on Exposure to Tamoxifen - Cmax ss

    Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios

    Time frame: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31

  2. Effect of Tamoxifen on Exposure to Olaparib - Cmax ss

    Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios

    Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31

  3. Effect of Olaparib on Exposure to Anastrozole - Cmax ss

    Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios

    Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24

  4. Effect of Anastrozole on Exposure to Olaparib - Cmax ss

    Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios

    Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24

  5. Effect of Olaparib on Exposure to Letrozole - Cmax ss

    Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios

    Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43

  6. Effect of Letrozole on Exposure to Olaparib - Cmax ss

    Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios

    Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43

  7. Effect of Olaparib on Exposure to Tamoxifen - AUC0-τ

    Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios

    Time frame: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31

  8. Effect of Tamoxifen on Exposure to Olaparib - AUC0-τ

    Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios

    Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31

  9. Effect of Olaparib on Exposure to Anastrozole - AUC0-τ

    Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios

    Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24

  10. Effect of Anastrozole on Exposure to Olaparib - AUC0-τ

    Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios

    Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24

  11. Effect of Olaparib on Exposure to Letrozole - AUC0-τ

    Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios

    Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43

  12. Effect of Letrozole on Exposure to Olaparib - AUC0-τ

    Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios

    Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43

07

Results

Posted Jun 1, 2016
Limitations and caveats
At the end of Part B, the continued access phase (CAP) allowed patients to continue to receive olaparib if deriving clinical benefit. No clinical data was databased during the CAP, thus AE data is presented to the end of Part B only.

Participant flow

First patient enrolled: 01 Sep 2014; last completed Part A: 28 Apr 2015. Last patient completed Part B: 27 Apr 2016. Part A assessed olaparib's effect on the pharmacokinetic (PK) parameters of anastrozole, letrozole and tamoxifen and vice versa; in Part B eligible patients received olaparib providing further safety data. Target accrual was met.

Part A
Participant flow — Part A
MilestoneCohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleOlaparib (Part B)
Started3023260
Completing treatment period 12922230
Completing treatment period 22921230
Completing treatment period 32821230
Completed2821230
Not completed2230
Withdrew: Adverse event0110
Withdrew: Condition under investigation worsened2020
Withdrew: Death0100
Part B
Participant flow — Part B
MilestoneCohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleOlaparib (Part B)
Started00069
Completed0006
Not completed00063
Withdrew: Patient decision0003
Withdrew: Disease progression0004
Withdrew: Complete response0001
Withdrew: Adverse event + disease progression0001
Withdrew: Lack of therapeutic response00012
Withdrew: Condition under investigation worsened00039
Withdrew: Adverse event0002
Withdrew: Death0001

Outcome measures

PrimaryEffect of Olaparib on Exposure to Tamoxifen - Cmax ss

Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios

Time frame:
Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
Reported as:
Geometric mean · mcg/mL
Effect of Olaparib on Exposure to Tamoxifen - Cmax ss
mcg/mLCohort 1 - Tamoxifen Alone (Treatment Period 2)Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3)
PK analysis of tamoxifen130.3 ± 27.3154.2 ± 34.9
PK analysis of N-DMT162.9 ± 28.0149.1 ± 44.8
PK analysis of endoxifen5.923 ± 65.75.727 ± 61.2
Statistical analysis
  • Cohort 1 - Tamoxifen Alone (Treatment Period 2) vs Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) · Gls mean ratio: 1.13 · 90% CI 1.06 to 1.22olaparib + tamoxifen vs. tamoxifen
PrimaryEffect of Tamoxifen on Exposure to Olaparib - Cmax ss

Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios

Time frame:
Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
Reported as:
Geometric mean · mcg/mL
Effect of Tamoxifen on Exposure to Olaparib - Cmax ss
mcg/mLCohort 1 - Olaparib (Treatment Period 1)Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3)
Effect of Tamoxifen on Exposure to Olaparib - Cmax ss9.456 ± 41.57.216 ± 43.6
Statistical analysis
  • Cohort 1 - Olaparib (Treatment Period 1) vs Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) · Gls mean ratio: 0.80 · 90% CI 0.71 to 0.90olaparib + tamoxifen vs. olaparib
PrimaryEffect of Olaparib on Exposure to Anastrozole - Cmax ss

Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios

Time frame:
Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
Reported as:
Geometric mean · micrograms per millilitre (mcg/mL)
Effect of Olaparib on Exposure to Anastrozole - Cmax ss
micrograms per millilitre (mcg/mL)Cohort 2 - Anastrozole Alone (Treatment Period 2)Cohort 2 - Olaparib + Anastrozole (Treatment Period 3)
Effect of Olaparib on Exposure to Anastrozole - Cmax ss40.98 ± 36.235.83 ± 31.9
Statistical analysis
  • Cohort 2 - Anastrozole Alone (Treatment Period 2) vs Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) · Geometric least squares (gls) mean ratio: 0.90 · 90% CI 0.84 to 0.97olaparib + anastrozole vs. anastrozole
PrimaryEffect of Anastrozole on Exposure to Olaparib - Cmax ss

Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios

Time frame:
Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
Reported as:
Geometric mean · mcg/mL
Effect of Anastrozole on Exposure to Olaparib - Cmax ss
mcg/mLCohort 2 - Olaparib (Treatment Period 1)Cohort 2 - Olaparib + Anastrozole (Treatment Period 3)
Effect of Anastrozole on Exposure to Olaparib - Cmax ss9.490 ± 34.38.256 ± 39.9
Statistical analysis
  • Cohort 2 - Olaparib (Treatment Period 1) vs Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) · Gls mean ratio: 0.94 · 90% CI 0.84 to 1.04olaparib + anastrozole vs. olaparib
PrimaryEffect of Olaparib on Exposure to Letrozole - Cmax ss

Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios

Time frame:
Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
Reported as:
Geometric mean · mcg/mL
Effect of Olaparib on Exposure to Letrozole - Cmax ss
mcg/mLCohort 3 - Letrozole Alone (Treatment Period 2)Cohort 3 - Olaparib + Letrozole (Treatment Period 3)
Effect of Olaparib on Exposure to Letrozole - Cmax ss118.9 ± 32.6111.8 ± 30.4
Statistical analysis
  • Cohort 3 - Letrozole Alone (Treatment Period 2) vs Cohort 3 - Olaparib + Letrozole (Treatment Period 3) · Gls mean ratio: 0.94 · 90% CI 0.91 to 0.98olaparib + letrozole vs. letrozole
PrimaryEffect of Letrozole on Exposure to Olaparib - Cmax ss

Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios

Time frame:
Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
Reported as:
Geometric mean · mcg/mL
Effect of Letrozole on Exposure to Olaparib - Cmax ss
mcg/mLCohort 3 - Olaparib (Treatment Period 1)Cohort 3 - Olaparib + Letrozole (Treatment Period 3)
Effect of Letrozole on Exposure to Olaparib - Cmax ss10.05 ± 30.210.48 ± 33.6
Statistical analysis
  • Cohort 3 - Olaparib (Treatment Period 1) vs Cohort 3 - Olaparib + Letrozole (Treatment Period 3) · Gls mean ratio: 1.09 · 90% CI 0.99 to 1.21olaparib + letrozole vs. olaparib
PrimaryEffect of Olaparib on Exposure to Tamoxifen - AUC0-τ

Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios

Time frame:
Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
Reported as:
Geometric mean · microgram x hour/millilitre (mcg*h/mL)
Effect of Olaparib on Exposure to Tamoxifen - AUC0-τ
microgram x hour/millilitre (mcg*h/mL)Cohort 1 - Tamoxifen Alone (Treatment Period 2)Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3)
PK analysis of tamoxifen2233 ± 31.92751 ± 28.9
PK analysis of N-DMT3189 ± 28.82955 ± 37.3
PK analysis of endoxifen119.3 ± 66.1115.8 ± 64.8
Statistical analysis
  • Cohort 1 - Tamoxifen Alone (Treatment Period 2) vs Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) · Gls mean ratio: 1.16 · 90% CI 1.11 to 1.21olaparib + tamoxifen vs. tamoxifen
PrimaryEffect of Tamoxifen on Exposure to Olaparib - AUC0-τ

Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios

Time frame:
Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
Reported as:
Geometric mean · mcg*h/mL
Effect of Tamoxifen on Exposure to Olaparib - AUC0-τ
mcg*h/mLCohort 1 - Olaparib (Treatment Period 1)Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3)
Effect of Tamoxifen on Exposure to Olaparib - AUC0-τ62.12 ± 51.642.27 ± 60.6
Statistical analysis
  • Cohort 1 - Olaparib (Treatment Period 1) vs Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) · Gls mean ratio: 0.73 · 90% CI 0.63 to 0.84olaparib + tamoxifen vs. olaparib
PrimaryEffect of Olaparib on Exposure to Anastrozole - AUC0-τ

Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios

Time frame:
Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
Reported as:
Geometric mean · mcg*h/mL
Effect of Olaparib on Exposure to Anastrozole - AUC0-τ
mcg*h/mLCohort 2 - Anastrozole Alone (Treatment Period 2)Cohort 2 - Olaparib + Anastrozole (Treatment Period 3)
Effect of Olaparib on Exposure to Anastrozole - AUC0-τ696.8 ± 36.6582.5 ± 31.6
Statistical analysis
  • Cohort 2 - Anastrozole Alone (Treatment Period 2) vs Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) · Gls mean ratio: 0.86 · 90% CI 0.80 to 0.93olaparib + anastrozole vs. anastrozole
PrimaryEffect of Anastrozole on Exposure to Olaparib - AUC0-τ

Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios

Time frame:
Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
Reported as:
Geometric mean · mcg*h/mL
Effect of Anastrozole on Exposure to Olaparib - AUC0-τ
mcg*h/mLCohort 2 - Olaparib (Treatment Period 1)Cohort 2 - Olaparib + Anastrozole (Treatment Period 3)
Effect of Anastrozole on Exposure to Olaparib - AUC0-τ55.49 ± 53.844.33 ± 63.6
Statistical analysis
  • Cohort 2 - Olaparib (Treatment Period 1) vs Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) · Gls mean ratio: 0.89 · 90% CI 0.76 to 1.05olaparib + anastrozole vs. olaparib
PrimaryEffect of Olaparib on Exposure to Letrozole - AUC0-τ

Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios

Time frame:
Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
Reported as:
Geometric mean · mcg*h/mL
Effect of Olaparib on Exposure to Letrozole - AUC0-τ
mcg*h/mLCohort 3 - Letrozole Alone (Treatment Period 2)Cohort 3 - Olaparib + Letrozole (Treatment Period 3)
Effect of Olaparib on Exposure to Letrozole - AUC0-τ2292 ± 36.72167 ± 38.0
Statistical analysis
  • Cohort 3 - Letrozole Alone (Treatment Period 2) vs Cohort 3 - Olaparib + Letrozole (Treatment Period 3) · Gls mean ratio: 0.95 · 90% CI 0.91 to 0.99olaparib + letrozole vs. letrozole
PrimaryEffect of Letrozole on Exposure to Olaparib - AUC0-τ

Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios

Time frame:
Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
Reported as:
Geometric mean · mcg*h/mL
Effect of Letrozole on Exposure to Olaparib - AUC0-τ
mcg*h/mLCohort 3 - Olaparib (Treatment Period 1)Cohort 3 - Olaparib + Letrozole (Treatment Period 3)
Effect of Letrozole on Exposure to Olaparib - AUC0-τ61.77 ± 43.267.82 ± 44.1
Statistical analysis
  • Cohort 3 - Olaparib (Treatment Period 1) vs Cohort 3 - Olaparib + Letrozole (Treatment Period 3) · Gls mean ratio: 1.15 · 90% CI 1.07 to 1.25olaparib + letrozole vs. olaparib

Adverse events

Collected over For Part A, adverse events (AEs) were collected from the date of first dose up to last dose of study medication in Part A for patients continuing to Part B, or up to 30 days after last dose for patients who did not enter Part B (up to approximately 2 months). For Part B, AEs were collected from date of first dose in Part B up to 30 days after last dose (up to approximately 18 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - Tamoxifen1/30 (3.3%)2/30 (6.7%)27/30 (90%)
Cohort 2 - Anastrozole1/23 (4.3%)0/23 (0%)20/23 (87%)
Cohort 3 - Letrozole1/26 (3.8%)0/26 (0%)20/26 (76.9%)
Olaparib (Part B)1/69 (1.4%)22/69 (31.9%)66/69 (95.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventCohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleOlaparib (Part B)
AnaemiaBlood and lymphatic system disorders0/300/230/265/69
AscitesGastrointestinal disorders1/300/230/260/69
VomitingGastrointestinal disorders1/300/230/261/69
Device OcclusionGeneral disorders0/300/230/262/69
Urinary Tract InfectionInfections and infestations0/300/230/262/69
UrosepsisInfections and infestations0/300/230/262/69
ConstipationGastrointestinal disorders0/300/230/262/69
Anaemia MacrocyticBlood and lymphatic system disorders0/300/230/261/69
TachycardiaCardiac disorders0/300/230/261/69
DiplopiaEye disorders0/300/230/261/69
Most frequent other events
Showing 10 of 54
Most frequent other events
EventCohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleOlaparib (Part B)
NauseaGastrointestinal disorders16/307/2311/2628/69
FatigueGeneral disorders12/306/239/2630/69
VomitingGastrointestinal disorders6/304/234/2622/69
AnaemiaBlood and lymphatic system disorders6/303/233/2618/69
DyspnoeaRespiratory, thoracic and mediastinal disorders3/302/231/2618/69
Decreased AppetiteMetabolism and nutrition disorders2/304/233/2613/69
DiarrhoeaGastrointestinal disorders5/301/233/2612/69
HeadacheNervous system disorders3/301/234/2612/69
CoughRespiratory, thoracic and mediastinal disorders1/302/231/2612/69
RashSkin and subcutaneous tissue disorders0/304/232/263/69

Baseline characteristics

All patients enrolled in Part A of the study and who received at least 1 dose of olaparib were included in the baseline analysis.

Age, Continuous
Age, Continuous(years)Cohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleTotal
Mean52.6 ± 11.3259.4 ± 11.6864.0 ± 7.7958.3 ± 11.37
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleTotal
Female26182064
Male45615
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleTotal
Female26182064
Male45615
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleTotal
Hispanic or Latino0000
Not Hispanic or Latino30232679
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 - TamoxifenCohort 2 - AnastrozoleCohort 3 - LetrozoleTotal
American Indian or Alaska Native0011
Asian1102
Native Hawaiian or Other Pacific Islander0000
Black or African American1012
White27222473
More than one race0000
Unknown or Not Reported1001
08

Study locations

14 sites
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Utrecht, 3584 CX, Netherlands
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sorensen P, De Greve J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Adv Ther. 2018 Nov;35(11):1945-1964. doi: 10.1007/s12325-018-0804-z. Epub 2018 Oct 15. PubMed 30324586 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Apr 2015, 7 months.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 7 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2014
First posted
Mar 21, 2014
StartActual
Sep 1, 2014
Primary completionActual
Apr 30, 2015
CompletionActual
Apr 29, 2019
Results first posted
Jun 1, 2016
Last update
Oct 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02093351
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 21, 2014
Start date
Sep 1, 2014
Primary completion
Apr 30, 2015
Completion
Apr 29, 2019
Results posted
Jun 1, 2016
Last update
Oct 2, 2019

Study contacts

Tsveta Milenkova
study director · AstraZeneca
Ruth Plummer
principal investigator · Sir Bobby Robson Cancer Trials Research Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Tamoxifen · Anastrozole · Letrozole

Start the discussion